GSK’s partner posts positive osteosarcoma data for B7-H3 drug, bolstering oncology push
I'm LongbridgeAI, I can summarize articles.GSK partner Hansoh Pharma reported positive Phase III ARTEMIS-011 trial data for risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma, showing significant progression-free survival improvement. This bolsters GSK's oncology pipeline as it advances Ris-Rez globally under exclusive rights outside Greater China. The drug is the first B7-H3-targeted ADC with positive Phase III outcomes across multiple tumor types. Analyst ratings on GSK remain mixed, with a 'Sell' consensus and 'Neutral' AI assessment citing solid financials offset by technical weakness.
The latest update is out from GlaxoSmithKline ( (GB:GSK) ).
GSK’s licensor Hansoh Pharma has reported that its phase III ARTEMIS-011 trial of risvutatug rezetecan (Ris-Rez) in Chinese patients with relapsed osteosarcoma achieved a statistically significant improvement in progression-free survival versus chemotherapy, with supporting gains in overall survival and no new safety signals. The data will underpin a regulatory filing in China and add to a growing late-stage evidence base for the B7-H3-targeted antibody-drug conjugate, including prior pivotal results in advanced or relapsed small-cell lung cancer.
Under its exclusive rights outside Greater China, GSK is advancing a global phase Ib/II study of Ris-Rez in advanced sarcomas as part of a broader programme across multiple solid tumours, including lung and prostate cancers, supported by multiple orphan drug and breakthrough therapy designations. The latest osteosarcoma results position Ris-Rez as the first B7-H3-targeted ADC with positive phase III outcomes across several tumour types, strengthening GSK’s competitive footing in oncology and offering a potential new option in a rare cancer with few established treatments after multiple prior lines of therapy.
The most recent analyst rating on (GB:GSK) stock is a Sell
with a £19.00 price target.
To see the full list of analyst forecasts on GlaxoSmithKline stock,
see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by solid underlying financial performance (strong margins and improved earnings) and supportive valuation (low P/E with a ~3.47% yield). These positives are partially offset by weak technical momentum (below key moving averages with negative MACD) and financial risk factors including meaningful leverage and uneven free-cash-flow consistency.
To see Spark’s full report on GSK stock,
click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on developing vaccines, specialty medicines and innovative oncology treatments, with a stated ambition to improve quality of life, extend survival and alter the course of disease. Its oncology strategy is expanding from blood and women’s cancers into lung, gastrointestinal and other solid tumours, with priority programmes centred on antibody-drug conjugates and targeted therapies.
Average Trading Volume: 8,226,559
Technical Sentiment Signal: Strong Buy
Current Market Cap: £76.89B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.